Fig. 1.
![Fig. 1. Binding of FITC-labeled Gp96 to PMNs and monocytes. / PBLs (2 × 105) were incubated with Gp96-FITC (50 μg/mL) and analyzed by FACS gating on PMNs (CD66b+) or monocytes (CD14+). Gp96-FITC binding was competed in the presence of 5 times excess of unlabeled Gp96 on PMNs (A) or monocytes (C), but not by IgG2b as irrelevant protein (PMNs [B] or monocytes [D]). (E) The summarized results of normalized LPS-FITC or Gp96-FITC binding to PMNs from 4 independent experiments are presented with standard deviation. LPS-FITC or Gp96-FITC binding was competed using fucoidan (1 mg/mL), unlabeled LPS (5-fold), or Gp96 (5-fold) (*P < .004; **P < .05, by Student t test).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/101/7/10.1182_blood-2002-07-2261/3/h80734063001.jpeg?Expires=1735832711&Signature=fVIsrQNgdz8X5gd-9UqkME8dBkuqiavGYPw63I1jGqBdXIoEBUL-ehntdl7Q7iNSGSvsMpry4XYN8FOWoqwM-pzXQi6Uy1ckn5xdEkYRGgwXmTQkKLPHzKPPvK2Z2GMkex70OPsDqOeSl9eAgVaaPLwUxigK9bMXOWiMEe~kPgi-vzYDTcJhQ5c8c2UPNBM9tFUasmQVXA-KlvQ4E~cPQLzjDtctKiGbVHKkrh5AxnxHksklp9p5bRU0ygtpMagez5ZnwqwbWBhB9qqnH3BlvGTPtiu2vQ12rOQsgtTdmBQ8Y6Tg9ELPWvkp~rkpLpc51FVjlu-cUiMY8PuF7Nz0Ww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Binding of FITC-labeled Gp96 to PMNs and monocytes.
PBLs (2 × 105) were incubated with Gp96-FITC (50 μg/mL) and analyzed by FACS gating on PMNs (CD66b+) or monocytes (CD14+). Gp96-FITC binding was competed in the presence of 5 times excess of unlabeled Gp96 on PMNs (A) or monocytes (C), but not by IgG2b as irrelevant protein (PMNs [B] or monocytes [D]). (E) The summarized results of normalized LPS-FITC or Gp96-FITC binding to PMNs from 4 independent experiments are presented with standard deviation. LPS-FITC or Gp96-FITC binding was competed using fucoidan (1 mg/mL), unlabeled LPS (5-fold), or Gp96 (5-fold) (*P < .004; **P < .05, by Student t test).
